NCT06922448

Study of BLU-808 in Allergic Rhinoconjunctivitis

A Phase 2a Randomized Double-blinded Placebo Controlled Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Clinical Activity of BLU-808, a Wild-type KIT Inhibitor, in Participants With Ragweed (Ambrosia Artemisiifolia)-Induced Allergic Rhinoconjunctivitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Blueprint Medicines Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (ARC). Participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (AEC).

Conditions

• Allergic Rhinoconjunctivitis

Interventions

Type	Name	Description
DRUG	BLU-808	BLU-808 tablets
DRUG	Placebo	Placebo tablets

Timeline

• Start date: 2025-04-14
• Primary completion: 2025-09-08
• Completion: 2025-09-08
• First posted: 2025-04-10
• Last updated: 2026-02-10

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study